Zai Lab Shares Rise Nearly 4% in Morning Trading; Company to Unveil First Clinical Data for ZL-1503 at 2026 ACAAI Meeting

Deep News10-15

Zai Lab (ZAI LAB) saw its shares climb nearly 4% in morning trading, with the stock up 3.72% as of press time to HK$18.13, on turnover of HK$25.9048 million.

According to the company, on October 14, Zai Lab announced that the first clinical study data evaluating ZL-1503 will be presented for the first time at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting.

ZL-1503 is an internally developed bispecific antibody targeting interleukin-13 (IL-13) and interleukin-31 (IL-31) receptor alpha.

The meeting will be held from November 12 to 16, 2026, in Phoenix, Arizona, in the United States.

The Phase 1/1b first-in-human trial results in healthy volunteers to be presented at ACAAI 2026 will include pharmacokinetic data following single dosing, as well as pharmacodynamic data on AD-related biomarkers at different ZL-1503 dose levels.

The ACAAI presentation will also include preliminary safety and immunogenicity data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment